Allogenetics Appoints Olaf Schermeier as Advisory Board Chairman

Hanover, Germany, October 01, 2026 /CourierPR/ -- Allogenetics has appointed Olaf Schermeier, PhD, as Chairman of its Advisory Board, a move that comes at a pivotal time for the company. Schermeier brings over 25 years of industry experience, including deep expertise in healthcare technology, organ replacement therapies, and transplantation.

Schermeier’s appointment is significant as Allogenetics prepares to transition its ALG-115, an ex vivo donor-organ gene therapy candidate, from preclinical stages towards its first-in-human clinical trials in lung transplantation. ALG-115 is designed to modify the donor organ prior to transplantation, aiming to prevent rejection while protecting graft immunocompetence. The goal is to eliminate the need for lifelong immunosuppression, thereby improving graft survival and patient quality of life.

Schermeier’s background is extensive, having held several senior leadership positions at Fresenius Medical Care, including serving on the Management Board as CEO of Research & Development and later as CEO of Critical Care & Ventures. At Fresenius, he led innovation, business development, and strategic investments in emerging healthcare technologies, including regenerative medicine and xenotransplantation. Earlier in his career, Schermeier held senior positions at Dräger Medical, Biotronik, and Charité, University Hospital Berlin. He also brings extensive board and advisory experience across a range of medtech and healthcare companies.

Allogenetics’ mission is to enable longer and healthier lives for transplant patients by fine-tuning the balance between immune tolerance and protection. The company’s proprietary technology platform enables a calibrated knockdown of cell-surface antigen presentation (MHC class I and II) to evade graft rejection while retaining full immune competence. Building on compelling proof-of-concept in animal models, Allogenetics aims to bring its novel organ-agnostic approach into human clinical trials, starting with lung grafts.

Allogenetics is advancing an ex vivo gene therapy designed as a one-time treatment to modify the donor organ, with the goal of reducing and potentially eliminating the need for lifelong immunosuppression. The company’s approach is aimed at addressing life-threatening conditions and the global organ shortage crisis.